{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:59:25Z","timestamp":1783699165430,"version":"3.55.0"},"reference-count":84,"publisher":"Radcliffe Medical Media Ltd","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Nicorandil and long-acting nitrates are vasodilatory drugs used commonly in the management of chronic stable angina pectoris. Both nicorandil and long-acting nitrates exert anti-angina properties via activation of nitric oxide (NO) signalling pathways, triggering vascular smooth muscle cell relaxation. Nicorandil has additional actions as an arterial K+<jats:sup>ATP<\/jats:sup>channel agonist, resulting in more \u201cbalanced\u201d arterial and venous vasodilatation than nitrates. Ultimately, these drugs prevent angina symptoms through reductions in preload and diastolic wall tension and, to a lesser extent, epicardial coronary artery dilatation and lowering of systemic blood pressure. While there is some evidence to suggest a modest reduction in cardiovascular events among patients with stable angina treated with nicorandil compared to placebo, this prognostic benefit has yet to be proven conclusively. In contrast, there is emerging evidence to suggest that chronic use of long-acting nitrates might cause endothelial dysfunction and increased cardiovascular risk in some patients.<\/jats:p>","DOI":"10.15420\/ecr.2018.9.2","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T16:01:32Z","timestamp":1535040092000},"page":"23","source":"Crossref","is-referenced-by-count":48,"title":["Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris"],"prefix":"10.15420","volume":"13","author":[{"given":"Jason M","family":"Tarkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Heart and Lung Institute, Imperial College London","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Division of Cardiovascular Medicine, University of Cambridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cardiovascular and Cell Sciences Research Institute, St George\u2019s, University of London","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Force Members","year":"2013","unstructured":"1. Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.","journal-title":"Eur Heart J"},{"key":"ref1","unstructured":"2. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60: e44-e164."},{"key":"ref2","unstructured":"3. National Institute for Health and Care Excellence. Management of stable angina. London: NICE; 2011. Available at: www.nice.org.uk\/CG126 (accessed 10 July 2018)."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","article-title":"Expert consensus document: A \"diamond\" approach to personalized treatment of angina","volume":"15","author":"Ferrari","year":"2018","unstructured":"4. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: A \"diamond\" approach to personalized treatment of angina. Nat Rev Cardiol 2018;15:120-32.","journal-title":"Nat Rev Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of coronary spasm by nicorandil: comparison with nifedipine. J Cardiovasc Pharmacol 1992;20(Suppl 3):S82-5.","DOI":"10.1097\/00005344-199206203-00014"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0002-9149(82)90521-5","article-title":"Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm","volume":"49","author":"Hill","year":"1982","unstructured":"6. Hill JA, Feldman RL, Pepine CJ, Conti CR. Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 1982;49:431-8.","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7861\/clinmedicine.13-1-63","article-title":"Pharmacological treatment of chronic stable angina pectoris","volume":"13","author":"JM","year":"2013","unstructured":"7. Tarkin JM, Kaski JC. Pharmacological treatment of chronic stable angina pectoris. Clin Med 2013;13:63-70.","journal-title":"Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1053\/euhj.2000.2152","article-title":"Therapeutic options for the management of patients with cardiac syndrome X","volume":"22","author":"JC","year":"2001","unstructured":"8. Kaski JC, Valenzuela Garcia LF. Therapeutic options for the management of patients with cardiac syndrome X. Eur Heart J 2001;22:283-93.","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10557-013-6439-z","article-title":"Lack of effect of nitrates on exercise stress test results in patients with microvascular angina","volume":"27","author":"Russo","year":"2013","unstructured":"9. Russo G, Di Franco A, Lamendola P, et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther 2013;27:229-34.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992;20(Suppl 3):S34-44.","DOI":"10.1097\/00005344-199206203-00008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Kukovetz WR, Holzmann S, P\u00f6ch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol 1992;20(Suppl 3):S1-7.","DOI":"10.1097\/00005344-199206203-00002"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Sumimoto K, Domae M, Yamanaka K, et al. Actions of nicorandil on vascular smooth muscles. J Cardiovasc Pharmacol 1987;10(Suppl 8):S66-75.","DOI":"10.1097\/00005344-198706108-00012"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/0002-9149(88)90933-2","article-title":"Coronary vasodilatory action after a single dose of nicorandil","volume":"61","author":"Suryapranata","year":"1988","unstructured":"13. Suryapranata H, Serruys PW, de Feyter PJ. Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol 1988;61:292-7.","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2005.06.053","article-title":"The effect of the K+ agonist nicorandil on peripheral vascular resistance","volume":"111","author":"Brodmann","year":"2006","unstructured":"14. Brodmann M, Lischnig U, Lueger A, et al. The effect of the K+ agonist nicorandil on peripheral vascular resistance. Int J Cardiol 2006;111:49-52.","journal-title":"Int J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00005344-199510000-00006","article-title":"Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels","volume":"26","author":"Akai","year":"1995","unstructured":"15. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995;26:541-7.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Treese N, Erbel R, Meyer J. Acute hemodynamic effects of nicorandil in coronary artery disease. J Cardiovasc Pharmacol 2006;20Suppl 3):S52-6.","DOI":"10.1097\/00005344-199206203-00010"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20(Suppl 3):S86-92.","DOI":"10.1097\/00005344-199206203-00015"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/0002-9149(86)90347-4","article-title":"Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris","volume":"58","author":"Kinoshita","year":"1986","unstructured":"18. Kinoshita M, Nishikawa S, Sawamura M, et al. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. Am J Cardiol 1986;58:733-8.","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0002-8703(86)90355-8","article-title":"Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study","volume":"112","author":"Hayata","year":"1986","unstructured":"19. Hayata N, Araki H, Nakamura M. Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. Am Heart J 1986;112:1245-50.","journal-title":"Am Heart J"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 1989;63:J61-5.","DOI":"10.1016\/0002-9149(89)90207-5"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Meany TB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989;63:J66-J70.","DOI":"10.1016\/0002-9149(89)90208-7"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Why HJ, Richardson PJ. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo. Eur Heart J 1993;14(Suppl B):25-9.","DOI":"10.1093\/eurheartj\/14.suppl_B.25"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/0002-9149(90)91129-T","article-title":"Comparison of nicorandil and atenolol in stable angina pectoris","volume":"66","author":"Hughes","year":"1990","unstructured":"23. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990;66:679-82.","journal-title":"Am J Cardiol"},{"key":"ref23","unstructured":"24. Meeter K, Kelder JC, Tijssen JG, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;20(Suppl 3):S59-66."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF00878320","article-title":"A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris","volume":"7","author":"Di Somma","year":"1993","unstructured":"25. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993;7:119-23.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(Suppl 3):S67-73.","DOI":"10.1097\/00005344-199206203-00012"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):30-4.","DOI":"10.1093\/eurheartj\/14.suppl_B.30"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. D\u00f6ring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20 Suppl 3:S74-81.","DOI":"10.1097\/00005344-199206203-00013"},{"key":"ref28","unstructured":"29. Lai C, Onnis E, Solinas R, et al. A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate. Cardiologia 1991;36:703-11 [in Italian]."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Ciampricotti R, Schotborgh CE, de Kam PJ, van Herwaarden RH. A comparison of nicorandil with isosorbide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. Am Heart J 2000;139:e1-9.","DOI":"10.1067\/mhj.2000.103846"},{"key":"ref30","unstructured":"31. SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213-7."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial","volume":"359","author":"Study Group","year":"2002","unstructured":"32. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75.","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/hrt.2003.026310","article-title":"Impact of nicorandil in angina: subgroup analyses","volume":"90","author":"Study Group","year":"2004","unstructured":"33. IONA Study Group. Impact of nicorandil in angina: subgroup analyses. Heart 2004;90:1427-30.","journal-title":"Heart"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/heartjnl-2011-301436","article-title":"Management of stable angina: summary of NICE guidance","volume":"98","author":"Henderson","year":"2012","unstructured":"34. Henderson RA, O'Flynn N, on behalf of the Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500-7.","journal-title":"Heart"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0735-1097(99)00539-2","article-title":"Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease","volume":"35","author":"Matsubara","year":"2000","unstructured":"35. Matsubara T, Minatoguchi S, Matsuo H. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000;35:345-51.","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0735-1097(99)00552-5","article-title":"Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels","volume":"35","author":"Sato","year":"2000","unstructured":"36. Sato T, Sasaki N, O'Rourke B, Marb\u00e1n E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000;35:514-8.","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/01.fjc.0000162771.00174.a8","article-title":"Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis","volume":"46","author":"Sekiya","year":"2005","unstructured":"37. Sekiya M, Sato M, Funada J, et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005;46:63-7.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/FJC.0b013e318163a95f","article-title":"Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease","volume":"51","author":"Ishibashi","year":"2008","unstructured":"38. Ishibashi Y, Takahashi N, Tokumaru A, et al. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease. J Cardiovasc Pharmacol 2008;51:311-6.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2010.11.032","article-title":"Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris","volume":"214","author":"Izumiya","year":"2011","unstructured":"39. Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011;214:415-21.","journal-title":"Atherosclerosis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00005344-199401000-00024","article-title":"Antiplatelet effects of a novel antianginal agent, nicorandil","volume":"23","author":"Jaraki","year":"1994","unstructured":"40. Jaraki O, Strauss WE, Francis S, et al. Antiplatelet effects of a novel antianginal agent, nicorandil. J Cardiovasc Pharmacol 1994;23:24-30.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1253\/circj.70.1099","article-title":"Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction - Sigmart multicenter angioplasty revascularization trial (SMART)","volume":"70","author":"Ota","year":"2006","unstructured":"41. Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction - Sigmart multicenter angioplasty revascularization trial (SMART). Circ J 2006;70:1099-104.","journal-title":"Circ J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10557-013-6456-y","article-title":"Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study","volume":"27","author":"Ito","year":"2013","unstructured":"42. Ito N, Nanto S, Doi Y, et al. Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study. Cardiovasc Drugs Ther 2013;27:279-87.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jjcc.2008.07.019","article-title":"Important factors for salvaging myocardium in patients with acute myocardial infarction","volume":"52","author":"Murakami","year":"2008","unstructured":"43. Murakami J, Toyama T, Adachi H, et al. Important factors for salvaging myocardium in patients with acute myocardial infarction. J Cardiol 2008;52:269-75.","journal-title":"J Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jjcc.2011.08.001","article-title":"Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction","volume":"59","author":"Sakata","year":"2012","unstructured":"44. Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012;59:14-21.","journal-title":"J Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/euhj.1998.1354","article-title":"Clinical European studies in angina and revascularization","volume":"20","author":"Patel","year":"1999","unstructured":"45. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J 1999;20:51-7.","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/(SICI)1099-1557(199905\/06)8:3<197::AID-PDS422>3.0.CO;2-T","article-title":"Safety profile of nicorandil - prescription-event monitoring (PEM) study","volume":"8","author":"Dunn","year":"1999","unstructured":"46. Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD. Safety profile of nicorandil - prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999;8:197-205.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J 1993;14 Suppl B:48-52.","DOI":"10.1093\/eurheartj\/14.suppl_B.48"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Witchitz S, Darmon JY. Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 1995;9 Suppl 2:237-43.","DOI":"10.1007\/BF00878471"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00878678","article-title":"Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers","volume":"9","author":"Kool","year":"1995","unstructured":"49. Kool MJ, Spek JJ, Struyker-Boudier HA, et al. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. Cardiovasc Drugs Ther 1995;9:331-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S0002-9149(99)00025-9","article-title":"Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris","volume":"83","author":"Rajaratnam","year":"1999","unstructured":"50. Rajaratnam R, Brieger DB, Hawkins R, Freedman SB. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 1999;83:1120-4.","journal-title":"Am J Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/S0140-6736(05)61045-8","article-title":"Association of major aphthous ulcers and nicorandil","volume":"352","author":"Agbo-Godeau","year":"1998","unstructured":"51. Agbo-Godeau S, Joly P, Lauret P, et al. Association of major aphthous ulcers and nicorandil. Lancet 1998;352:1598-9.","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0140-6736(02)09710-6","article-title":"Nicorandil associated anal ulceration","volume":"360","author":"Watson","year":"2002","unstructured":"52. Watson A, Ozairi OA, Fraser A, et al. Nicorandil associated anal ulceration. Lancet 2002;360:546-7.","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53. Fung HL, Chung SJ, Bauer JA, et al. Biochemical mechanism of organic nitrate action. Am J Cardiol 1992;70:4B-10.","DOI":"10.1016\/0002-9149(92)90588-P"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/eurheartj\/eht384","article-title":"Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"35","author":"M\u00fcnzel","year":"2014","unstructured":"54. M\u00fcnzel T, Meinertz T, Tebbe U, et al. Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial. Eur Heart J 2014;35:895-903.","journal-title":"Eur Heart J"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00392-007-0588-7","article-title":"New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance","volume":"97","author":"Daiber","year":"2007","unstructured":"55. Daiber A, Wenzel P, Oelze M, M\u00fcnzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2007;97:12-20.","journal-title":"Clin Res Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1161\/01.CIR.0000094403.78467.C3","article-title":"Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3',5-'cyclic monophosphate-dependent protein kinase","volume":"108","author":"M\u00fcnzel","year":"2003","unstructured":"56. M\u00fcnzel T, Feil R, M\u00fclsch A, et al. Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3',5-'cyclic monophosphate-dependent protein kinase. Circulation 2003;108:2172-83.","journal-title":"Circulation"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/BF00877117","article-title":"Mechanisms of action of nitrates","volume":"8","author":"Torfg\u00e5rd KE","year":"1994","unstructured":"57. Torfg\u00e5rd KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994;8:701-17.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00018-011-0815-2","article-title":"Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle","volume":"69","author":"Morgado","year":"2012","unstructured":"58. Morgado M, Cairr\u00e3o E, Santos-Silva AJ, Verde I. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci 2012;69:247-66.","journal-title":"Cell Mol Life Sci"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59. Thadani U. Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther 1997;11(Suppl 1):213-8.","DOI":"10.1023\/A:1007750706831"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/01.CIR.64.2.324","article-title":"Magnitude of dilatation of large and small coronary arteries of nitroglycerin","volume":"64","author":"Feldman","year":"1981","unstructured":"60. Feldman RL, Pepine CJ, Conti CR. Magnitude of dilatation of large and small coronary arteries of nitroglycerin. Circulation 1981;64:324-33.","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/0002-9149(93)91098-3","article-title":"Eccentric dosing with isosorbide-5-mononitrate in angina pectoris","volume":"72","author":"Parker","year":"1993","unstructured":"61. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993;72:871-6.","journal-title":"Am J Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/0002-9149(87)91087-3","article-title":"Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris","volume":"59","author":"Thadani","year":"1987","unstructured":"62. Thadani U, Hamilton SF, Olson E, Anderson JL. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 1987;59:756-62.","journal-title":"Am J Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/hrt.66.2.151","article-title":"The Transdermal Nitrate Investigators","volume":"66","author":"Fox","year":"1991","unstructured":"63. Fox KM, Dargie HJ, Deanfield J, Maseri A. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. The Transdermal Nitrate Investigators. Br Heart J 1991;66:151-5.","journal-title":"Br Heart J"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0002-9149(84)90233-9","article-title":"Transdermal nitroglycerin in angina pectoris","volume":"54","author":"JO","year":"1984","unstructured":"64. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471-6.","journal-title":"Am J Cardiol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40256-014-0072-5","article-title":"Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance","volume":"14","author":"Thadani","year":"2014","unstructured":"65. Thadani U. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance. Am J Cardiovasc Drugs 2014;14:287-301.","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1161\/01.CIR.84.6.2336","article-title":"Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin","volume":"84","author":"Parker","year":"1991","unstructured":"66. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circ 1991;84:2336-45.","journal-title":"Circ"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijcard.2010.05.019","article-title":"Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials","volume":"146","author":"Wei","year":"2011","unstructured":"67. Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol 2011;146:4-12.","journal-title":"Int J Cardiol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/0002-9149(93)90292-K","article-title":"Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris","volume":"72","author":"Chrysant","year":"1993","unstructured":"68. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249-56.","journal-title":"Am J Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/01.CIR.77.6.1376","article-title":"Antianginal effects of intravenous nitroglycerin over 24 hours","volume":"77","author":"Zimrin","year":"1988","unstructured":"69. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circ 1988;77:1376-84.","journal-title":"Circ"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1161\/01.CIR.0000036743.07406.53","article-title":"Nitrate tolerance: a unifying hypothesis","volume":"106","author":"Gori","year":"2002","unstructured":"70. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circ 2002;106:2510-3.","journal-title":"Circ"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jacc.2006.10.074","article-title":"Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism","volume":"49","author":"Thomas","year":"2007","unstructured":"71. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007;49:1289-95.","journal-title":"J Am Coll Cardiol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/S0735-1097(98)00456-2","article-title":"Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine","volume":"32","author":"Caramori","year":"1998","unstructured":"72. Caramori PR, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998;32:1969-74.","journal-title":"J Am Coll Cardiol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0735-1097(00)01140-2","article-title":"Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine","volume":"37","author":"Azevedo","year":"2001","unstructured":"73. Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001;37:505-9.","journal-title":"J Am Coll Cardiol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0735-1097(00)00754-3","article-title":"Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production","volume":"36","author":"M\u00fcnzel","year":"2000","unstructured":"74. M\u00fcnzel T, Mollnau H, Hartmann M, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 2000; 36:628-34.","journal-title":"J Am Coll Cardiol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1253\/jcj.60.779","article-title":"Secondary Prevention Group","volume":"60","author":"Ishikawa","year":"1996","unstructured":"75. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996;60:779-88.","journal-title":"Jpn Circ J"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-8703(99)70163-8","article-title":"Multicenter Myocardial Ischemia Research Group","volume":"138","author":"Nakamura","year":"1999","unstructured":"76. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999;138:577-85.","journal-title":"Am Heart J"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2017.07.031","article-title":"Impact of different nitrate therapies on long-term clinical outcomes of patients with vasospastic angina: a propensity score-matched analysis","volume":"252","author":"Kim","year":"2018","unstructured":"77. Kim CH, Park TK, Cho SW, et al. Impact of different nitrate therapies on long-term clinical outcomes of patients with vasospastic angina: a propensity score-matched analysis. Int J Cardiol 2018;252:1-5.","journal-title":"Int J Cardiol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/eurheartj\/ehu313","article-title":"Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association","volume":"36","author":"Takahashi","year":"2015","unstructured":"78. Takahashi J, Nihei T, Takagi Y, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J 2015;36:228-37.","journal-title":"Eur Heart J"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/eurheartj\/ehp457","article-title":"Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events","volume":"31","author":"Ambrosio","year":"2010","unstructured":"79. Ambrosio G, Del Pinto M, Tritto I, et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010;31:430-8.","journal-title":"Eur Heart J"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.jacc.2017.09.1064","article-title":"The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics","volume":"70","author":"Divakaran","year":"2017","unstructured":"80. Divakaran S, Loscalzo J. The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics. J Am Coll Cardiol 2017;70:2393-410.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"ref80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10557-016-6668-z","article-title":"Vasodilator therapy: nitrates and nicorandil","volume":"30","author":"JM","year":"2016","unstructured":"81. Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther 2016; 30(4):367-78.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/00045391-199612000-00003","article-title":"Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage","volume":"3","author":"Cleophas","year":"1996","unstructured":"82. Cleophas TJ, Niemeyer MG, van der Wall EE. Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. Am J Ther 1996;3:802-6.","journal-title":"Am J Ther"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1476-5381.2010.00643.x","article-title":"Headache-type adverse effects of NO donors: vasodilation and beyond","volume":"160","author":"Bagdy","year":"2010","unstructured":"83. Bagdy G, Riba P, Kecskem\u00e9ti V, et al. Headache-type adverse effects of NO donors: vasodilation and beyond. Brit J Pharmacol 2010;160:20-35.","journal-title":"Brit J Pharmacol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.5.5.667","article-title":"Side effects of using nitrates to treat angina","volume":"5","author":"Thadani","year":"2006","unstructured":"84. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Saf 2006;5:667-74.","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articles\/nicorandil-and-long-acting-nitrates-vasodilator-therapies-management-chronic-stable-angina","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T14:10:33Z","timestamp":1751811033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articles\/nicorandil-and-long-acting-nitrates-vasodilator-therapies-management-chronic-stable-angina"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["ecr.2018.9.2"],"URL":"https:\/\/doi.org\/10.15420\/ecr.2018.9.2","relation":{},"ISSN":["1758-3756"],"issn-type":[{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}